Optimi Health appoints Chief Clinical Development Officer
Optimi Health Corp. appointed Dr. Michael Blough as Chief Clinical Development Officer, overseeing planned Phase 2 psilocybin and Phase 3 MDMA trials expected to begin enrolling next year.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Optimi Health appoints Dr. Michael Blough Chief Clinical Development Officer
Optimi Health said it appointed Dr. Michael Blough as Chief Clinical Development Officer, supporting its planned Phase 2 psilocybin trial in major depressive disorder and Phase 3 MDMA trial in PTSD.
OPTH - Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
OPTH - Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer